Additional chromosome abnormalities in chronic myeloid leukemia
The Philadelphia (Ph) chromosome and/or Breakpoint cluster region-Abelson leukemia virus oncogene transcript are unique markers for chronic myeloid leukemia (CML). However, CML demonstrates heterogeneous presentations and outcomes. We analyzed the cytogenetic and molecular results of CML patients to...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-02-01
|
Series: | Kaohsiung Journal of Medical Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1607551X10000239 |
id |
doaj-3437dc2609074b7ab32e2c906972690b |
---|---|
record_format |
Article |
spelling |
doaj-3437dc2609074b7ab32e2c906972690b2020-11-25T00:50:43ZengWileyKaohsiung Journal of Medical Sciences1607-551X2011-02-01272495410.1016/j.kjms.2010.09.001Additional chromosome abnormalities in chronic myeloid leukemiaHui-Hua Hsiao0Yi-Chang Liu1Hui-Jen Tsai2Jui-Feng Hsu3Wen-Chi Yang4Chao-Sung Chang5Sheng-Fung Lin6蕭惠樺7劉益昌8蔡慧珍9許瑞峰10楊文祺11張肇松12林勝豐13Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanThe Philadelphia (Ph) chromosome and/or Breakpoint cluster region-Abelson leukemia virus oncogene transcript are unique markers for chronic myeloid leukemia (CML). However, CML demonstrates heterogeneous presentations and outcomes. We analyzed the cytogenetic and molecular results of CML patients to evaluate their correlation with clinical presentations and outcome. A total of 84 newly diagnosed CML patients were enrolled in the study. Patients were treated according to disease status. Bone marrow samples were obtained to perform cytogenetic and molecular studies. Clinical presentations, treatment courses, and survival were reviewed retrospectively. Among 84 patients, 72 had chronic phase and 12 had accelerated phase CML. Cytogenetic study showed 69 (82.1%) with the classic Ph chromosome, 6 (7.2%) with a variant Ph chromosome, and 9 (10.7%) with additional chromosome abnormalities. Fifty-four (64.3%) cases harbored b3a2 transcripts, 29 (34.5%) had b2a2 transcript, and 1 had e19a2 transcript. There was no difference in clinical presentations between different cytogenetic and molecular groups; however, additional chromosome abnormalities were significantly associated with the accelerated phase. Imatinib therapy was an effective treatment, as measured by cytogenetic response, when administered as first- and second-line therapy in chronic phase patients. Survival analysis showed that old age, additional chromosome abnormalities, high Sokal score, and no cytogenetic response in second-line therapy had a significant poor impact (p<0.05). In conclusion, we presented the cytogenetic and molecular pattern of CML patients and demonstrated that the additional chromosome abnormality was associated with poor outcome.http://www.sciencedirect.com/science/article/pii/S1607551X10000239Additional chromosome abnormalityBCR-ABLChronic myeloid leukemiaVariant Philadelphia chromosome |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hui-Hua Hsiao Yi-Chang Liu Hui-Jen Tsai Jui-Feng Hsu Wen-Chi Yang Chao-Sung Chang Sheng-Fung Lin 蕭惠樺 劉益昌 蔡慧珍 許瑞峰 楊文祺 張肇松 林勝豐 |
spellingShingle |
Hui-Hua Hsiao Yi-Chang Liu Hui-Jen Tsai Jui-Feng Hsu Wen-Chi Yang Chao-Sung Chang Sheng-Fung Lin 蕭惠樺 劉益昌 蔡慧珍 許瑞峰 楊文祺 張肇松 林勝豐 Additional chromosome abnormalities in chronic myeloid leukemia Kaohsiung Journal of Medical Sciences Additional chromosome abnormality BCR-ABL Chronic myeloid leukemia Variant Philadelphia chromosome |
author_facet |
Hui-Hua Hsiao Yi-Chang Liu Hui-Jen Tsai Jui-Feng Hsu Wen-Chi Yang Chao-Sung Chang Sheng-Fung Lin 蕭惠樺 劉益昌 蔡慧珍 許瑞峰 楊文祺 張肇松 林勝豐 |
author_sort |
Hui-Hua Hsiao |
title |
Additional chromosome abnormalities in chronic myeloid leukemia |
title_short |
Additional chromosome abnormalities in chronic myeloid leukemia |
title_full |
Additional chromosome abnormalities in chronic myeloid leukemia |
title_fullStr |
Additional chromosome abnormalities in chronic myeloid leukemia |
title_full_unstemmed |
Additional chromosome abnormalities in chronic myeloid leukemia |
title_sort |
additional chromosome abnormalities in chronic myeloid leukemia |
publisher |
Wiley |
series |
Kaohsiung Journal of Medical Sciences |
issn |
1607-551X |
publishDate |
2011-02-01 |
description |
The Philadelphia (Ph) chromosome and/or Breakpoint cluster region-Abelson leukemia virus oncogene transcript are unique markers for chronic myeloid leukemia (CML). However, CML demonstrates heterogeneous presentations and outcomes. We analyzed the cytogenetic and molecular results of CML patients to evaluate their correlation with clinical presentations and outcome. A total of 84 newly diagnosed CML patients were enrolled in the study. Patients were treated according to disease status. Bone marrow samples were obtained to perform cytogenetic and molecular studies. Clinical presentations, treatment courses, and survival were reviewed retrospectively. Among 84 patients, 72 had chronic phase and 12 had accelerated phase CML. Cytogenetic study showed 69 (82.1%) with the classic Ph chromosome, 6 (7.2%) with a variant Ph chromosome, and 9 (10.7%) with additional chromosome abnormalities. Fifty-four (64.3%) cases harbored b3a2 transcripts, 29 (34.5%) had b2a2 transcript, and 1 had e19a2 transcript. There was no difference in clinical presentations between different cytogenetic and molecular groups; however, additional chromosome abnormalities were significantly associated with the accelerated phase. Imatinib therapy was an effective treatment, as measured by cytogenetic response, when administered as first- and second-line therapy in chronic phase patients. Survival analysis showed that old age, additional chromosome abnormalities, high Sokal score, and no cytogenetic response in second-line therapy had a significant poor impact (p<0.05). In conclusion, we presented the cytogenetic and molecular pattern of CML patients and demonstrated that the additional chromosome abnormality was associated with poor outcome. |
topic |
Additional chromosome abnormality BCR-ABL Chronic myeloid leukemia Variant Philadelphia chromosome |
url |
http://www.sciencedirect.com/science/article/pii/S1607551X10000239 |
work_keys_str_mv |
AT huihuahsiao additionalchromosomeabnormalitiesinchronicmyeloidleukemia AT yichangliu additionalchromosomeabnormalitiesinchronicmyeloidleukemia AT huijentsai additionalchromosomeabnormalitiesinchronicmyeloidleukemia AT juifenghsu additionalchromosomeabnormalitiesinchronicmyeloidleukemia AT wenchiyang additionalchromosomeabnormalitiesinchronicmyeloidleukemia AT chaosungchang additionalchromosomeabnormalitiesinchronicmyeloidleukemia AT shengfunglin additionalchromosomeabnormalitiesinchronicmyeloidleukemia AT xiāohuìhuà additionalchromosomeabnormalitiesinchronicmyeloidleukemia AT liúyìchāng additionalchromosomeabnormalitiesinchronicmyeloidleukemia AT càihuìzhēn additionalchromosomeabnormalitiesinchronicmyeloidleukemia AT xǔruìfēng additionalchromosomeabnormalitiesinchronicmyeloidleukemia AT yángwénqí additionalchromosomeabnormalitiesinchronicmyeloidleukemia AT zhāngzhàosōng additionalchromosomeabnormalitiesinchronicmyeloidleukemia AT línshèngfēng additionalchromosomeabnormalitiesinchronicmyeloidleukemia |
_version_ |
1725246848686358528 |